Dapagliflozin Prevents Kidney Glycogen Accumulation and Improves Renal Proximal Tubule Cell Functions in a Mouse Model of Glycogen Storage Disease Type 1b-Reference-Cited by-同舟云学术

Dapagliflozin Prevents Kidney Glycogen Accumulation and Improves Renal Proximal Tubule Cell Functions in a Mouse Model of Glycogen Storage Disease Type 1b

Published:2022-10 Issue:10 Volume:33 Page:1864-1875
ISSN:1046-6673
Container-title:Journal of the American Society of Nephrology
language:en
Short-container-title:JASN

Author:

D’Acierno Mariavittoria,Resaz Roberta,Iervolino Anna,Nielsen Rikke,Sardella Donato,Siccardi Sabrina,Costanzo Vincenzo,D’Apolito Luciano,Suzumoto Yoko,Segalerba Daniela,Astigiano Simonetta,Perna Alessandra F.,Capasso Giovambattista,Eva Alessandra,Trepiccione Francesco

Funder

Telethon Foundation

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Nephrology,General Medicine

Reference33 articles.

1. Vitamin E supplementation improves neutropenia and reduces the frequency of infections in patients with glycogen storage disease type 1b;Melis;Eur J Pediatr,2009

2. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: Results of the European Study on Glycogen Storage Disease type I;Visser;J Pediatr,2000

3. Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1;Visser;Eur J Pediatr,2002

4. Inactivation of the glucose 6-phosphate transporter causes glycogen storage disease type 1b;Hiraiwa;J Biol Chem,1999

5. Type I glycogen storage diseases: Disorders of the glucose-6-phosphatase complex;Chou;Curr Mol Med,2002

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin attenuates AKI to CKD transition in diabetes by activating SIRT3/PGC1-α signaling and alleviating aberrant metabolic reprogramming;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-10

2. Impaired Glucose Metabolism, Primary Cilium Defects, and Kidney Cystogenesis in Glycogen Storage Disease Type Ia;Journal of the American Society of Nephrology;2024-08-14

3. Sodium-Dependent Glucose Transporter Type 2 Inhibitors as a Breakthrough in Neutropenia and Neutrophil Dysfunction Management in Patients with Glycogen Storage Disease Type Ib;Current Pediatrics;2024-07-12

4. Sodium-glucose cotransporter-2 inhibitors: A potential novel treatment for Lafora disease?;Pharmacological Research;2024-01

5. The SGLT2 inhibitor dapagliflozin improves kidney function in glycogen storage disease XI;Science Translational Medicine;2023-11